Researching for a Cure

Citizens United for Research in Epilepsy

Spring 2020
EVERY DAY WITH EPILEPSY...

...is an unknown. Some days, life can seem perfectly normal. Other days are filled with seizures and setbacks. Yet every day, our community faces this condition with courage as we continue to search for a cure.

At CURE, we’re researching every day for those living with epilepsy. As the only nonprofit organization solely focused on epilepsy research, we’ve spent the last two decades seeking to understand the underlying causes of this condition, uncover promising therapies, and ultimately find a cure. The road is long, and we get closer with every day, every scientific breakthrough, and every gesture of support from our community.

In this issue of “Researching for a Cure,” we share some of the most exciting discoveries that have filled our days over the past few months, including:

- Assembling a team of 60+ collaborators at institutions across the globe to research how to predict, treat, and prevent post-traumatic epilepsy
- Uncovering one of the biggest risk factors for SUDEP – as well as recommendations to reduce those risks
- Deepening our understanding of epilepsies caused by GRIN gene mutations

You’ll also hear inspiring stories from members of our community, including a young college student navigating school and life with epilepsy, and a CURE researcher who revealed his own struggles with epilepsy at a recent CURE event.

Every day, we’re researching for you – and we won’t stop until we find a cure. Thank you for your support, today and every day.

Beth Lewin Dean
CURE IS RESEARCHING...

**BASIC MECHANISMS OF EPILEPSY**
**SUDDEN UNEXPLAINED DEATH IN EPILEPSY (SUDEP)**
**SLEEP AND EPILEPSY**
**ACQUIRED EPILEPSY**

**OVER 80%**
OF CURE RESEARCH FUNDS INVESTED IN BASIC SCIENCE SINCE 2011

**RESEARCH SPOTLIGHT:**
Focal cortical dysplasias (FCDs) are a common cause of focal epilepsy, a difficult-to-treat condition that often requires surgery. CURE grantee Dr. Yu Wang and his team used a gene editing technique to develop a groundbreaking animal model of FCD, revealing that an existing therapy may be effective in treating focal epilepsy.

**20X**
PEOPLE WITH EPILEPSY ARE 20X MORE LIKELY TO DIE SUDDENLY THAN THE GENERAL POPULATION.

**OVER $4 MILLION**
IN SUDEP GRANTS AWARDED TO DATE

**2017**
CURE ESTABLISHED SLEEP AND EPILEPSY AS A KEY RESEARCH PRIORITY, ATTEMPTING TO BETTER UNDERSTAND THE RELATIONSHIP BETWEEN SLEEP AND EPILEPSY IN THE HOPE OF IMPROVED TREATMENT OPTIONS

**UP TO 25%**
OF PATIENTS HAVE PREDOMINANTLY NOCTURNAL SEIZURES.

**4.2%**
OF ALL U.S. TROOPS WHO SERVED FROM 2000 TO 2011 WERE DIAGNOSED WITH A TRAUMATIC BRAIN INJURY, MAKING THEM ESPECIALLY SUSCEPTIBLE TO DEVELOPING POST-TRAUMATIC EPILEPSY.

**RESEARCH SPOTLIGHT:**
CURE grantee Dr. Judy Liu and her team at Brown University are studying whether seizures are more likely to occur in certain stages of sleep, ultimately leading to a better understanding of sleep and epilepsy and potential new strategies to manage these seizures. This research was generously funded by the BAND Foundation.

---


---

**30+**
RESEARCH PROJECTS

---

---

---

---
CURE IS RESEARCHING...

RESEARCH SPOTLIGHT:

A new treatment for Dravet syndrome, a rare and catastrophic form of treatment-resistant epilepsy, could become a reality thanks to research from two CURE grantees in Australia. Dr. Glenn King and Dr. Stefan Petrou identified a peptide in spider venom that successfully reduced seizures and mortality in mice experiencing Dravet symptoms.

Since its inception, CURE has been at the forefront of epilepsy research, raising over $70 million to fund research and other programs that will lead the way to a cure for epilepsy.
For many U.S. troops, the gravest injuries suffered in combat aren’t always the visible ones.

The changing nature of combat has made traumatic brain injury (TBI) a major health concern for service members, both during times of conflict and in daily life. Brought on by blast exposures, vehicle crashes, and other impacts to the head, TBI can increase the chance of developing post-traumatic epilepsy (PTE), a debilitating condition defined by recurrent seizures. Research from the Vietnam, Afghanistan, and Iraq wars has shown sharply increased rates of PTE in troops who sustained TBI.

Research also shows PTE represents approximately 20% of all symptomatic epilepsy cases, occurring among veterans and civilians alike. Currently, there is no way to predict or prevent PTE, and treatment options are often ineffective and can have severe side effects. With hundreds of thousands of service members diagnosed with TBI since 2000, the need for innovation in research is clear.

KEY FACTS

OVER 400,000
U.S. MILITARY PERSONNEL, DIAGNOSED WITH TBI FROM 2000-2019

53%
OF VIETNAM VETERANS WHO SUFFERED FROM SEVERE TBI THAT REQUIRED NEUROSURGERY SUBSEQUENTLY DEVELOPED EPILEPSY

19X
A GROUP OF AFGHANISTAN AND IRAQ WAR VETERANS WITH TBI WERE APPROXIMATELY 19X MORE LIKELY TO DEVELOP EPILEPSY THAN THOSE WITHOUT TBI

Research also shows PTE represents approximately 20% of all symptomatic epilepsy cases, occurring among veterans and civilians alike. Currently, there is no way to predict or prevent PTE, and treatment options are often ineffective and can have severe side effects. With hundreds of thousands of service members diagnosed with TBI since 2000, the need for innovation in research is clear.

CURE’s newest signature research effort, the Post-Traumatic Epilepsy Initiative, is an ambitious multidisciplinary program that seeks answers for veterans and others affected by this condition. Funded through a $10 million U.S. Department of Defense grant, the Initiative takes an innovative team science approach to better understand the causes of post-traumatic epilepsy, which may one day support development of new treatments. Through this work, CURE investigators aim to develop:

- Effective new models for studying PTE
- Biomarkers to identify someone’s risk of developing PTE following a TBI that lead to therapies to prevent or halt PTE

Inside the Initiative

CURE's newest signature research effort, the Post-Traumatic Epilepsy Initiative, is an ambitious multidisciplinary program that seeks answers for veterans and others affected by this condition. Funded through a $10 million U.S. Department of Defense grant, the Initiative takes an innovative team science approach to better understand the causes of post-traumatic epilepsy, which may one day support development of new treatments. Through this work, CURE investigators aim to develop:

- Effective new models for studying PTE
- Biomarkers to identify someone’s risk of developing PTE following a TBI
- Therapies to prevent or halt PTE
To address this complex issue, the Post-Traumatic Epilepsy Initiative brings together more than 60 researchers from across the globe. The initiative features six research teams across multiple institutions, each with a specific focus related to TBI and PTE.

Under the oversight of CURE, the Department of Defense, and an external advisory council, the investigators exchange data, materials, and models in real time as they work toward shared goals. This approach allows the initiative to adapt as researchers share findings, informing the program’s overall direction to make the outcomes as impactful as possible. Through collaboration and shared discovery, the initiative aims to provide results that can improve the lives of people everywhere living with post-traumatic epilepsy.

**Taking on PTE as a Team**

**THE POWER OF DATA**

In partnership with the University of Southern California’s Laboratory for Neuro Imaging, the Post-Traumatic Epilepsy Initiative is creating a database to store team data for cross-comparison and analysis, as well as electronic case report forms with common data elements for clinical and preclinical TBI.

The initiative is also supporting the International League Against Epilepsy/American Epilepsy Society Joint Translational Task Force’s efforts to develop electronic case report forms containing common data elements for preclinical epilepsy research. Using common elements will help to increase rigor, transparency, and reproducibility in epilepsy research.

**Meet the Team**

**Harvard Medical School**

**Principal Investigator:** Dr. Kevin Staley

Dr. Staley and his team are exploring changes in the brain’s neuronal support system after TBI in a new animal model of PTE as well as in humans with moderate to severe TBI, with the goal of providing new insight into how PTE develops and new methods to identify high-risk patients.

**University of Pennsylvania**

**Principal Investigator:** Dr. Victoria Johnson

Using a novel animal model along with human tissue from those affected by TBI, Dr. Johnson and her team are studying the relationship between the detrimental neural changes that can follow TBI and the development of PTE.

**Mid-Atlantic Epilepsy and Sleep Center**

**Principal Investigator:** Dr. Pavel Klein

Dr. Klein and his team plan to examine a group of patients at high risk for PTE, searching for biomarkers in patients’ EEG signatures, MRIs, or blood that can help predict who is at an increased risk of developing this condition.

**Virginia Tech**

**Principal Investigator:** Dr. Harald Sontheimer

In response to the need for additional animal models of PTE, Dr. Sontheimer and his team are investigating the ways TBI leads to PTE in both an established as well as a new mouse model of PTE.

**University of Florida**

**Principal Investigator:** Dr. Kevin Wang

Using a mouse model of TBI, Dr. Wang and his team are seeking to uncover the unique chemical and molecular processes that lead to PTE following TBI, offering potential new focus areas and biomarkers for developing treatments.

**University of Illinois, Chicago**

**Principal Investigator:** Dr. Jeffrey Loeb

Focusing on an animal model as well as humans with subarachnoid hemorrhage, a common type of bleeding following TBI, Dr. Loeb and his team are utilizing EEG and imaging to uncover potential biomarkers for PTE.
You’ve spent nearly 40 years researching epilepsy. What initially drew you to this field of study?

When I began graduate school in 1980, I knew that I wanted to study neuroscience, but I knew very little about epilepsy. However, I soon realized that epilepsy as a field of study was extremely interesting to me, and how seizures start and spread. I realized quickly that understanding the mechanisms of action of antiepileptic drugs and the role of the non-neuronal glial cell in seizure onset and progression. Dr. Woodbury was a strong advocate for his students. At every meeting we attended, he would take me and his other students under his wing and introduce us to the greater epilepsy community. The more scientists and clinicians I met, the more I began to appreciate the passion they had for their work and their patients.

You’ve played a role in the development of several new antiseizure drugs and served in multiple leadership roles throughout your career. What are your proudest achievements?

I have been humbled by the support from the entire family of dedicated individuals I’ve been fortunate to work with over the years. Since 1993, the Anticonvulsant Drug Development Program at the University of Utah has touched all of the new antiseizure drugs on the market in some way. To know that this work contributed to the clinical advancement of several new antiseizure drugs has been extremely motivating and rewarding for the entire team. On a personal note, I think a lot about how our work together over the years has contributed to a better quality of life and seizure control for people living with epilepsy. Being the beneficiary of one of the antiseizure drugs first screened by the University of Utah Program, I am reminded twice daily how modern science and drug discovery can change lives by bringing new therapies to the marketplace. In addition, the team at Utah has been able to advance new animal models for drug screening, work that has impacted how the National Institute of Neurological Disorders and Stroke’s Epilepsy Therapy Screening Program evaluates new drugs. I am so pleased to see how this work continues today under the leadership of Dr. Karen Wilcox. I am also so proud of my work with CURE, particularly the Infantile Spasms and Post-Traumatic Epilepsy Initiatives. I have over the years been humbled by the support from the entire CURE family, not only for me but for all people with epilepsy and their families.

After a generalized tonic-clonic seizure in 2010, you were eventually diagnosed with focal epilepsy. How has your diagnosis impacted your personal and professional life?

In that moment, I got my first glimpse into what the lives of 60 million people with epilepsy must be like on a daily basis. I can honestly say that there’s not a day that goes by that I don’t think about it, and how it’s impacted me and my family. I remember waking up in the emergency department and being told that I had had a seizure, but not to worry because “everyone gets their first seizure for free.” Even though I tried to rationalize the seizure on the basis of sleep deprivation and stress, I knew enough about the disease state to know that no one gets any seizure for free and that there was likely an underlying cause that could not be so easily dismissed. If I have ever wanted to be wrong, it was that night. Unfortunately, shortly after an MRI the next morning, I found myself meeting with the Chief of Neuroradiology at the University of Utah discussing neurosurgery to remove an unidentified mass that the MRI had identified in my brain. When the pathology report suggested that my tumor was a low-grade nonmalignant brain tumor, I realized that I was very fortunate to have incredible access to the healthcare system and the best doctors and health care team at a time when I needed it. That’s something I fear doesn’t exist for a large percentage of people faced with a similar situation.

You were fortunate to find a treatment that has helped you control your focal seizures. How do you continue to manage your epilepsy day to day?

Eighteen months after the neurosurgery, I started having focal events that were becoming more frequent and longer in duration. In my mind, I realized these were probably focal seizures and I had prepared myself for the diagnosis. No matter how much I had prepared myself, hearing the words “focal epilepsy” was the start of a very long and painful journey. I felt that in order to have a diagnosis for a disease that I had studied for my entire career, and that I was taking an antiepileptic drug that was first screened by the team I directed during my tenure at the University of Utah, it was certain that I was personalized how important science is and that we cannot stop seeking better treatments for this disease.

You publicly announced your epilepsy diagnosis at the American Epilepsy Society (AES) conference last year. What inspired you to share this news with the community?

It was a decision that took me years to make. I remember a conversation with Susan Axelrod and Dr. Don Lowenstein a number of years earlier about how the landscape for epilepsy research might change if those of us with the disease were able to speak out and take ownership. Easier said than done, I told myself. I, like many others, felt almost paralyzed by the stigma that still exists around epilepsy. I worried about how my friends and colleagues would react. My decision to go public slowly evolved over the last two years. The last two summers, I’ve been fortunate to travel to Ghana on a Global Brigades Medical Mission, where we interviewed a number of people with epilepsy and their caregivers in an effort to understand their needs and how the 65% treatment gap was affecting their access to healthcare and medications. I wanted to share my story, thinking that in some way it might help ease their pain and anxiety, but I couldn’t find my voice. Long story short, I finally figured out that I could no longer sit silent. I have found great solace in being able to speak openly about what life is like with epilepsy. The diagnosis no longer controls me; I control it by being open with friends, colleagues, and students and there is no longer a reason for me to hide. I’ve been very lucky, and I hope that my story can drive science and advocacy forward to ultimately help others.

After I shared my story at AES, I was moved by the level of support I received. People kept coming up to me to tell me that they or a child had been personally affected by epilepsy. I couldn’t think of a better place to have had that conversation than with the CURE family present. I will always cherish the warmth that I felt, and I will be eternally grateful for the support that was shared with me and my wife, Kathryn, that night.

What are your hopes for the future of epilepsy research?

If I have one big hope, I don’t want to be standing here 20 years from now and still not have a cure or a treatment for those patients with treatment-resistant epilepsy. My hope is that we can use the knowledge of an ever-evolving science to finally find that transformative therapy that will someday alter or prevent the development of epilepsy in the susceptible individual. To do that, we need to all be strong advocates for epilepsy research and provide assurance that it is okay to talk about epilepsy.

“Being the beneficiary of one of the antiseizure drugs first screened by the University of Utah Program, I am reminded twice daily how modern science and drug discovery can change lives by bringing new therapies to the marketplace.”

DR. H. STEVE WHITE, UNIVERSITY OF WASHINGTON
RESEARCH HIGHLIGHTS

UNCOVERING RESISTANT EPILEPSY

THE REALITY

N-Methy-D-aspartate receptors (NMDA-R) are an essential component of electrical signaling in the brain and have recently been linked to many epilepsies. NMDA-Rs are made up of proteins encoded by the GRIN family of genes. Mutations in GRIN genes can therefore impact how NMDA-R works.

THE RESEARCH

Dr. Stephen Traynelis and his team at Emory University are looking into previously unstudied GRIN gene mutations to see which ones produce a strong overactivation of NMDA-R, making them potential candidates for off-label treatment with drugs that reduce NMDA-R function.8 The team has also created a registry where patients with GRIN mutations can sign up to determine if they are good candidates for these off-label treatments.

THE RESULTS

The team plans to evaluate how effective these treatments are for patients, providing clues into whether particular GRIN mutations may be better-suited for these treatments than others. The study is expected to provide data for a clinical trial, which could lead to new therapies for these difficult-to-treat epilepsies.

UNCOVERING NEW RISK FACTORS FOR SUDEP

THE REALITY

People living with epilepsy are at higher risk of unexplained death, but the reasons largely remain a mystery. To address this devastating phenomenon, scientists are working to uncover what puts people at greater risk of sudden unexplained death in epilepsy (SUDEP).

THE RESEARCH

By analyzing the medical records of more than 250 people who died from SUDEP, Dr. Torbjörn Tomson at the Karolinska Institute in Sweden and his team recognized a common thread: generalized tonic-clonic seizures (GTCS). While GTCS was the most important risk factor, the team found that sleeping alone heightened those risks even more.9

THE RESULTS

This data confirms previous research showing that unattended generalized tonic-clonic seizures are the biggest risk factor for SUDEP. These findings suggest that improved seizure monitoring devices, sleeping with someone else in the room when possible, and treatments to reduce seizures could all be potentially lifesaving interventions for people with GTCS.

HOW CAN YOU REDUCE YOUR SUDEP RISK?

CONSIDER NIGHTTIME SUPERVISION OR MONITORING

TAKE MEDICATION AS PRESCRIBED

KEEP A SEIZURE DIARY, AND AVOID SEIZURE TRIGGERS

TAKE CARE OF YOURSELF: EAT WELL, GET ENOUGH REST, AND EXERCISE REGULARLY

KEEP STRESS TO A MINIMUM


WHAT ARE GRIN GENES?

The glutamate ionotropic receptor NMDA type subunit (GRIN) family of genes make proteins that form NMDA-R, an essential component of electrical signaling in the brain. Mutations in these genes can affect how the NMDA-R works, resulting in certain types of epilepsies.
Congratulations to Our

CURE GRANTEES

A life free from seizures is the driving goal of CURE’s epilepsy research program, which supports novel projects with a focus on identifying, preventing, and treating epilepsy. We’re delighted to announce the recipients of our 2019 CURE grants, who join a growing team of investigators around the globe working toward a cure.

CURE EPILEPSY AWARD GRANTEES
$250,000 FOR TWO YEARS
This award reflects CURE’s continued focus on scientific advances that have the potential to truly transform the lives of those affected by epilepsy.

Heather Mefford, MD, PhD
University of Washington
Dr. Mefford and her team will explore if a process called “abnormal methylation” is a cause of severe pediatric epilepsy syndromes known as developmental and epileptic encephalopathies.

Nicholas Varvel, PhD
Emory University
Dr. Varvel and his team will focus on status epilepticus – a neurological emergency with a seizure lasting more than five minutes or when a person doesn’t return to consciousness following multiple seizures. Building on previous findings, the team plans to test an approach to relieve the detrimental effects of these seizures.

Christopher Reid, PhD
Florey Institute, Australia
Dr. Reid and his team will work to identify key SUDEP risk factors by developing new rodent models that replicate having both epilepsy and a genetic heart abnormality.

TAKING FLIGHT AWARD GRANTEE
$100,000 FOR ONE YEAR
This award seeks to promote the careers of young epilepsy investigators, allowing them to develop a research focus independent of their mentors.

Bin Gu, PhD
University of North Carolina at Chapel Hill
Dr. Gu and his team plan to use a unique resource – genetically diverse mice – to identify genes that increase susceptibility to SUDEP.

POST-TRAUMATIC EPILEPSY INITIATIVE GRANTEES

Pavel Klein, MD
Mid-Atlantic Epilepsy and Sleep Center
Dr. Klein and his team plan to address the current inability to predict who will go on to develop PTE following a traumatic brain injury by examining a group of high-risk patients with a greater chance of developing PTE.

Jeffrey Loeb, MD, PhD
University of Illinois, Chicago
Dr. Loeb and his team are studying subarachnoid hemorrhage, a type of bleeding that commonly occurs following a brain injury and is known to produce seizures. Their goal is to understand and predict who is at risk for developing this condition to identify potential treatment strategies.

Learn more about the Initiative on page 10.

As the leader in epilepsy research, CURE provides educational insights to empower patients and families as they navigate life with epilepsy.
LEADERS IN EPILEPSY RESEARCH WEBINAR SERIES

These webinars dive deep into the latest breakthroughs in diagnosing, treating, and controlling epilepsy, helping patients, families, and caregivers understand the clinical side of this condition. Explore the most innovative developments in epilepsy research today.

EPILEPSY EDUCATION FROM EVERY ANGLE

EPILEPSY EMERGENCIES AND CURRENT RESCUE MEDICATIONS
DR. KAMIL DETYNIECKI
UNIVERSITY OF MIAMI
DR. NATHAN FOUNTAIN
UNIVERSITY OF VIRGINIA

When a seizure becomes an emergency, rescue medications are a critical lifeline to provide relief and prevent the need for emergency care. In this special two-part webinar, leading experts on this topic explore different types of seizure emergencies, current therapies, and promising research that could lead to new effective rescue medications.

EPILEPSY SURGERY: ADVANCEMENTS, OPTIONS, & CONSIDERATIONS
DR. KATE DAVIS
UNIVERSITY OF PENNSYLVANIA

Surgery can be life-changing for patients with uncontrolled epilepsy. As this area of epilepsy research and treatment evolves, this webinar highlights the types of surgeries currently available to patients, potential risks and benefits, and who is an appropriate candidate for surgery.

EPILEPSY AND DIETARY THERAPIES
DR. JONG RHO
UNIVERSITY OF CALIFORNIA SAN DIEGO
DR. ERIC KOSSOFF
JOHNS HOPKINS CHILDREN’S CENTER

Can changing your diet help control seizures? This webinar discusses dietary therapies from a research and clinical perspective, including the effectiveness of the ketogenic diet and which patients are the best candidates for this type of treatment.

EXPLORE UPCOMING TOPICS AND REGISTER FOR OUR LIVE WEBINARS AT cureepilepsy.org/webinars

SEIZING LIFE®

The Seizing Life® podcast series chronicles the daily frustrations and triumphs of living with epilepsy, inspiring empathy and providing insight to our community as we search for a cure. Here’s a closer look at some of the stories that have touched our lives.

Epilepsy Surgery: Advancements, Options, & Considerations
Dr. Kate Davis
University of Pennsylvania

Surgery can be life-changing for patients with uncontrolled epilepsy. As this area of epilepsy research and treatment evolves, this webinar highlights the types of surgeries currently available to patients, potential risks and benefits, and who is an appropriate candidate for surgery.

Epilepsy and Dietary Therapies
Dr. Jong Rho
University of California San Diego
Dr. Eric Kossoff
Johns Hopkins Children’s Center

Can changing your diet help control seizures? This webinar discusses dietary therapies from a research and clinical perspective, including the effectiveness of the ketogenic diet and which patients are the best candidates for this type of treatment.

You’re Never Too Young to Be a Hero
Henry and Nancy Iida

After having a seizure in gym class while his classmates watched, Henry Iida knew he wanted to find a way to fight back. With his mother’s help, he’s raised $50,000 for epilepsy through Henry’s Heroes.

Surviving (And Thriving) in College with Epilepsy
Eva and Michelle Wadzinski

College is a big transition for any student — so what’s it like for a student living with epilepsy? Eva and her mother, Michelle, share how she’s balancing the stresses of college with her condition and strategies that can help make college easier for others with epilepsy.

Knowing the Signs of Infantile Spasms
Amy Grin Miller, Executive Director, Child Neurology Foundation

Infantile spasms is a rare and severe form of epilepsy, making swift detection essential to prevent cognitive and developmental delays. In this episode, Miller shares what parents should look for and what to do next if their child has spasms.

Tackling Life with PTE and CTE
Mike Adamle

A former NFL player and broadcaster, Adamle shares his 20-year fight against the effects of post-traumatic epilepsy and how he’s working to give hope to others dealing with the condition.

Testing Can Make a Difference
Dr. John Millichap, Pediatric Epileptologist, Ann and Robert H. Lurie Children’s Hospital of Chicago

With hundreds of epilepsy-related genes, how can you know if you or your child are a candidate for genetic testing? In this episode, Dr. Millichap discusses the basics of epilepsy genetics and the potential power of testing for patients and their families.

“I really do think we’re changing the conversation from how epilepsy used to be viewed even 10 or 20 years ago.”
Nancy Iida

Want more inspiration?
Check out the full series at cureepilepsy.org/seizing-life
From our annual benefit to local block parties and fundraisers, our supporters are making a difference in the search for a cure in so many ways.
Coming Together as a Community

We danced and sang. We shared stories of joy and loss. And we walked away energized and hopeful about our shared mission: to find a cure for epilepsy.

Thank you to everyone who’s shown up for CURE and the epilepsy community this year. Your support continues to fuel amazing progress in epilepsy research.

$2 million raised at our ANNUAL benefit

Epilepsy Conference

Epilepsy Awareness Day

Disneyland

Purple Day
THANK YOU TO OUR CHAMPIONS

Heroes come in all sizes at CURE. Our CURE Champions had their most successful fundraising year ever, raising nearly $375,000 to advance lifesaving research for epilepsy. Large or small, every gesture of generosity makes a big difference.

WHAT DOES CURE CHAMPIONS SUPPORT?
NEARLY $375,000 RAISED IN 2019 =
1 CURE EPILEPSY AWARD ($250,000)
1 TAKING FLIGHT AWARD ($100,000)
“We won’t stop fighting, advocating, and raising imperative research dollars. Because no family should have to go through this kind of loss, but way too many of us have.”

KELLY CERVANTES
CURE IS RESEARCHING FOR...

**ADELAIDE**

I will never stop advocating on [Adelaide’s] behalf, raising awareness and money for research so that families in the future will receive their epilepsy or neuro-degenerative diagnoses along with a treatment plan to full recovery. I promise...that I will fight for science to catch up to the next child, even though it could never catch up to her.”

**KELLY CERVANTES,** ADREAIDE’S MOTHER

Adelaide passed away in 2019 from complications from epilepsy, days before her 4th birthday.

**VERA**

While treatment is so helpful, ultimately it doesn’t end our fear or struggle. In fact, the medicine that stopped Vera’s recent seizures has been known to lead to permanent blindness. So medicine in the long run is not ideal. What we need is a cure.”

**ELVIN AND CINDY ANGULO,** VERA’S PARENTS

1-year-old Vera has Sturge Weber Syndrome, a rare condition that causes vision issues and epilepsy.

**CLARE**

I’m one of the lucky ones because I finally found a drug that works for my epilepsy. Never finding a proper drug should not be something that happens. Thanks to CURE’s Educational Enrichment Fund scholarship, I plan to major in biological sciences and eventually to help patients as both a clinician and researcher.”

**CLARE TYLER**

The Educational Enrichment Fund supports students so they can become agents of change in the epilepsy community. Meet all the 2019 scholars at cureepilepsy.org/scholarships.

**PAT**

Pat has tried several medications (for his post-traumatic epilepsy) but continues to suffer from seizures. At this point, I fear our options are running out.”

**PATTY HORAN,** PAT’S WIFE

Pat developed post-traumatic epilepsy after being shot during a mission in Iraq in 2007. Learn more about CURE’s newest research initiative on post-traumatic epilepsy on page 10.

**MICHAEL**

You can’t let the bad times stop you from doing what you love.”

**MICHAEL PLATT**

14-year-old Michael started cupcake company Michaels Desserts to combat hunger. After an epilepsy diagnosis prevented him from activities like gymnastics and diving, Michael discovered his passion for baking. Watch Michael share his story with David Axelrod at cureepilepsy.org/michaelsdesserts.

At CURE, we’re researching every day for those living with epilepsy.

AND SO MANY MORE...
2019 DONOR LIST

We depend on your support every day.
Every day, we move one step closer to curing epilepsy—and we’re humbled to have you with us along the journey.

Thank you for your support.

While space permits us to only list some of our 4,500+ donors, our gratitude for every gift is limitless. Each and every donation is critical to driving epilepsy research forward toward a cure. Thank you.

To donate to CURE, please visit CUREEPILEPSY.ORG/DONATE/2020SPRING

Fiscal Year 2019: January 1 to December 31

cureepilepsy.org | 39
Osprey Foundation
Mariana and Joe Parke
PrismaneCooper LLC
Judith Pomerantz
Michael Poldby
Emmet R. Quady Foundation
Julia and Robert Ramirez
Polly and Kenneth Ratner
Laura Ricketts and Brooke Skinner Ricketts
Jennifer and Jeffrey Robinson
Paula Robinson-Drake
Lori Rothkoff and Michael Canter
Amy Rule and The Honorabile Rahm Emanuel
Bethyl Saltmann and Paul Saltmann
Martha Sayes
Marjorie and Matthew Schneider
Kristin and Andrew Seaborg
Richard Silversia
Andrea and Marty Singer
SI Life Science Inc.
Andrea Lakin Solow and Alan Solow
Chic Stemp
Steve Quick Jewellers
The Strategy Group
Michael Swell
Margaret and Joseph Tolson
Patricia and Daniel Uehman
Cate and Frederick Waddell
The Walsh Foundation; Patty and Dan Walsh
Mr. Eric Weil
Reggie White
Heather and Tom Wurzer
VanTrust Real Estate, LLC

$2,500–$4,999
Ariel Investments
Sidney Austin LLP
Austen Science Foundation
Susan and Andrew Arnold
SC Benjamin Foundation
Kathy and Jeff Berg
James Bohnet
Jeffrey Boukler
Mary Cain
CAMEX
Chicago AMWA Consortium
Timothy Cool
Pat J and James Cunnane
Sara and David Decoste
Julia and Richard Diaisio
Cameron Dodd
Kathy and Bob Dodd
Joanna Edgell
Jackie and Alfred George
Anna Giannoulias
Sam Gonzaless
Nick and Matthew Hauck
Sheila Jewerand
Kate Kichkan and Paul Kivach
Gale and Mark Kazoff
Donna LaPietro and Bill Kurtis
Toby and Greg Lewis
Mary and Larry Liebischer
John Little
Steve Lunt
Laura and Donald MacDonald
Andrew Mathews
Peggy and Mike Meagher
Caroline Moran
Members of the Nelson Family
Stefania O’Keefe
Michele and Mark Patterson
Anna and Raymond Pittera
Patti and Kenneth Raskin
Loretta and Michael Robinson
Lori Sapos
Christina and Zac Schneider
Erin Scheid and David Schonhalt
Gene Schoen
Lisa and Randy Siegel
Doug Smith
Holly Stern
Linda and Donald Stewart
Theater at the Center
Triford Foundation
Terrence and Laura Travis
Barbara and Michael Urbat
Bruce Wedel
Cathy and John Wheeler
Connie Wisher
Clarkson C. Worner

$1,000–$2,499
Michael Abrams
Jennifer Addy
American Idol Broadway Family
Cindy and Elvin Angulo
The Arcelia Family
Matthew Armas
Linda and Jesse Avett
Ethan Axwold
Amher Bag
Lisa and Timothy Bazeemore
Kathleen and Melvin Bedre
Theresa Behrle-Mohs and Richard Mohs
Cheryl Bell
Elizabeth Bell
Gwyneth Bent
Lance Bigelow
Carolyn and Richard Block
Carolyn and William Blodgett
Michele Borough
Derek Bradfitt
Jennifer Breen
Lori and Robert Brennan
Julie and Keith Brunini
Sally Candamone
Michael Cardizzo
Emily and Matthew Carr
Colin Carter
Steven Casey
Diago Calayeta
Megan and Kim Chacon
Chas Cline
John Clark
Michael Clark
Kathryn Caleste Coats
Patricia Collins and Gordon Greenberg
Denise and Vincent Comparto
Sarah and William Cool
Kate and Matthew Cooper
Patricia and Paul Hartnett
Sarah Hegeman
John Heilemann
John Heyman
Kay Heinrichs
Helaina and Peter Heydemann
Aminta Hixman
Mallory Hoffman
Robbi Lawrence Hoffman
Christopher Hollinger
Terry Hong
Abbey Horowitz
John Hunt
Janet and David Hyland
Rick Jascula
Julie Jensen
Kerry and Mark Jaslow
Edward Johnson
Sally and William Johnson
Melanie Korberg
Kathleen and Glen Kaufman
Susan and Jules Kaufman
Jackie Kazarian and Peter Cunningham
Colin Kealey
Barbara Kelly
Colleen Kenyon and Chris Thome
Jana and Jeff Filbach
Cherriass Fischer
Lynn Fleshler and John Roberts
Brenda Fleischer
Maureen Flood
Illecia Frenn
Mary Frey and William Bennett
Meghan Friend
Mary Gager
Onion Galey
Lois and Dennis Gates
Roger Gay
Stephanie Geary
Gemini Gymnastics Academy
Gerber Family Fund
Tomas Gomzy
Jarred Green
Brian Greenleas
Tessi and Gary Grefer
Edith Gregson and Erik Smith
Lisa Guatson
Inna Halperin
Amanda Hannah
Deborah and James Hardin
Donald Harmon
Lee Hewt Harrison
Michelle and John Hart
Patricia and Paul Hartnett
Sarah Hegeman
John Heilemann
John Heyman
Kay Heinrichs
Helaina and Peter Heydemann
Aminta Hixman
Mallory Hoffman
Robbi Lawrence Hoffman
Christopher Hollinger
Terry Hong
Abbey Horowitz
John Hunt
Janet and David Hyland
Rick Jascula
Kerry and Mark Jaslow
Edward Johnson
Sally and William Johnson
Melanie Korberg
Kathleen and Glen Kaufman
Susan and Jules Kaufman
Jackie Kazarian and Peter Cunningham
Colin Kealey
Barbara Kelly
Colleen Kenyon and Chris Thome
Deborah Keyes
Kiwane Club of Orlando Park
Hann Kittinger
Daniel Kohnen
Sally Koons
Kathy Kapl
Francine and William Krakauer
Prema Krishnan
Nancy and Paul Kurland
Kevin Lada
Warren Lammert
Michael Leavitt
Colleen and James Lee
Lynne Levey
Jill and John Levi
Davie Lichtenhof
Katherine Linzer
Jeffrey Loeb
Jacqueline Logan and Whitney Magdiner
Mr. and Mrs. Barry Long
Roberto Longo
Stephanie Lowell and Gregg Duthaler
Don L. Lowenstein
Laura Lubbers and Trent Buck
Francesca Maggi
The Mollen Family
Peter Mark
Kim and Donald Matthews
Sarah Matthews
Nancy Mattice
Garrett McCarthy
Sophie McCarthy and Arthur Horvanc
McClelland Family Foundation
Brigg McGrath
Lark-Marie Manchini
Tom Mandel
Mercedes-Benz of Des Moines
Sandra and Andrew Merrill
Hanna and John Massiehr
Maggie Michelson
Laura Milani
Krystia and Michael Miller
Janice and Ken Minnes
Janet and Paul Moore
Kenneth Moore
Stephen Moore
David Morrisey
Kathleen and John Morrisey
Luis Morales
Darcy and Andrew Motuhol
Beth and Mark Myers
Sara and Patrick Nash
Cecilia Mollak Nish
John Noah
Linda Norby
Michelle Obama and The Honorabile Barack Obama
Kelley and Sean Owen
Pfizer Foundation
Pamela Phillips
Brenda Pluger
Maro and David Pohl
Samantha Pollina
Tanya Pop
Shaym and Elizabeth Prabhaharan
Rebecca Anhage Price and Matthew Price
Melissa Quick
Stephanie Rea
Lisa Reyes
Lauren and Edward Rirmian
Jeanine Ringland-Zwem and Howard Zwem
Louise Roberts
Elizabeth Robinson and Gordon Robinson
Kathleen and Fred Robinson
Anna and Kyle Rockey
Jennifer Ross
Priscilla and Russell Ros
Lauren Rosen
Laura and David Ross
Barbara Rothney
Kellie and Kris Sadens
Hamed Saded
St. Patrick’s Episcopal Day School
Christiane and Philip Salvador
Colman Savage
Morgan Scanlan Brown
Michelle Schaeffer
Morgan Scholl
Diane Scherberth
Erich Schnirbke
Robin Schirmar and John Baum
Andy Schimp
Susan Schneider and James Schneider
Wame and Marty Schrero
Michael Schultz
Glen Schwartz
Jack Segal
Select Equity Group Foundation
Rosalind and Khang Son
Donna Stevenson
Apy Shah
Ravshankar Sharmugam
Tracy and Lawrence Shar
Robert Shultz
Cassia Shimak
Simplus
2019 DONOR LIST (CONTINUED)

$1,000–$2,499 (CONTINUED)

William Singer
Brian Sinotte
Roz Slovo
Michael Slovis
Charles Smith
Susan Soergel
Dana Soltam
Heidi Steiner and Daniel Weiss
Susan Steinberg and Neil Cohen
Candice Steller
Amy and David Stender
Paul Stovall
Carolyn Strick
Nancy and Stephen Summers
Eileen Sutula and Thomas Sutula
Kim and Robert Swider
Andrew and Anthony Tahlier
Pnina Tcherbak
Vera Taylor
Vicki Taylor-Reskopf
Bill Terlato
Alexa Tolubock
Laura Tucker and Peter Giangreco
Mike Turner
Brian Tweedie
Edwin Uomi
Robert Vanekos
Claudia Wagner and Don Lebowitz
The Waldman Family Charitable Trust
Margaret and Brian Warhurst
Bruce Warws
Barbara Weide and Michael Goc
Sanford Weinstein
Travis Wilcox
West Monroe Partners
Whitaker/Ellis
Laura and Bruce White
Eleanor Wingard
Matthew Wilcox
Jam and Daniel Willison
Mary Willoughby
Laura Wise
Linda and John Woodford
Faya Yang
John Yanover
Jamie Zeek
Judith Zwein

CURE CHAMPIONS 2019

126 The Art of Epilepsy - Boston
21-Day Detox
24-Hour Livestream for a CURE
All-Guard Auto Alarm
Barry’s Bootcamp
Bla Bla Dry Grand Opening
Charitable Cars Donation
Comic Book Launch
Carol’s Crusaders Fundraiser
Criteo Fundraiser
Diamond Paint-A-Thon
Dressage for a Cause
Easter Basket Candy Drive
Ella’s Race for a CURE
Epilepsy Stigma Awareness Event
Epilepsy: Up Close and Personal (Chicago Salon)
Evan’s Facebook Campaign
Fitzgerald Physical Therapy
Golf Outing Fundraiser
Fundraiser for Olivia
Gala’s Twitch Fundraiser
Girl Scout Troop Fundraiser
Golf Outing Fundraiser
Hamishcare Fundraiser
Hamiltons
House of Blues Concert
Ice Cream for a CURE
Indy Mini Marathon
Josi’s Song Benefit Concert
Jumpathon at Altitude
Kuder Wedding Gifts
Lamorna Robert’s UK Trivia Event
Land Grant Brewing Celebration
Lauren Runs for a CURE
Lemonade for Adelaide
Lori Sapos Photo Shoot
Million Dollar Quartet
Molly’s Birthday Fundraiser
Mother’s Day T-shirt Sale
Orange Theory Fundraiser
Past Wars
Purple Day Concert
Purple Ribbon Gaming Event
Quiz for a Cause Trivia Night
Race For Epilepsy
Raw Gamers Twitch Stream
Rock for a CURE
Salesforce Concert
School Fundraiser
Sean’s 1st Birthday
Shutouts for Seizures
Silent Auction for a CURE
Skate for Alex
Songs of Love and Revolution
Stacha for a CURE
Team CURE - Chicago Half-Marathon
Team CURE - NYC Marathon
Teresa’s Birthday Benefit
UMES Strides for Epilepsy 5K
Vera’s Birthday Fundraiser
Wizard World Comic Con Chicago
Womens Empowerment Symposium
Yoga for a CURE

EADDL 2019 photos thanks to Brian Kramer Photography
Ella’s Race photos thanks to Lauren Enright Photography